Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
chronic lymphocytic leukaemia
ofatumumab
physician choice
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
06
09
2019
accepted:
08
11
2019
pubmed:
30
1
2020
medline:
13
1
2021
entrez:
30
1
2020
Statut:
ppublish
Résumé
In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician's choice. The five-year follow-up of this phase 3 trial showed that ofatumumab therapy resulted in a numerically but not significantly longer overall survival. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small-molecule inhibitors. Ofatumumab is a well-tolerable treatment option in multiresistant advanced CLL.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Vidarabine
FA2DM6879K
ofatumumab
M95KG522R0
fludarabine
P2K93U8740
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-693Subventions
Organisme : Novartis
Pays : International
Informations de copyright
© 2019 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Eketorp, S.S., Hansson, L., Karlsson, C., Norin, S., Lundin, J. & Osterborg, A. (2014) Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leukemia & Lymphoma, 55, 1774-1780.
Hallek, M.H., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H. & Stilgenbauer, S.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet, 376, 1164-1174.
Hallek, M., Shanafelt, T.D. & Eichhorst, B. (2018) Chronic lymphocytic leukaemia. The Lancet, 391, 1524-1537.
van Oers, M.H., Kuliczkowski, K., Smolej, L., Petrini, M., Offner, F., Grosicki, S., Levin, M.D., Gupta, I., Phillips, J., Williams, V., Manson, S., Lisby, S., Geisler, C.; PROLONG Study Investigators. (2015) Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology, 16, 1370-1379.
Österborg, A., Udvardy, M., Zaritskey, A., Andersson, P.O., Grosicki, S., Mazur, G., Kaplan, P., Steurer, M., Schuh, A., Montillo, M., Kryachok, I., Middeke, J.M., Kulyaba, Y., Rekhtman, G., Gorczyca, M., Daly, S., Chang, C.N., Lisby, S. & Gupta, I. (2016) Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & Lymphoma, 57, 2037-2046.
Pawluczkowycz, A.W., Beurskens, F.J., Beum, P.V., Lindorfer, M.A., van de Winkel, J.G., Parren, P.W. & Taylor, R.P. (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. Journal of Immunology, 183, 749-758.
Teeling, J.L., French, R.R., Cragg, M.S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P.W., Hack, C.E., Dechant, M., Valerius, T., van de Winkel, J.G. & Glennie, M.J. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104, 1793-1800.
Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W., Glennie, M.J. & van de Winkel, J.G. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology, 177, 362-371.
Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A.; Hx-CD20-406 Study Investigators. (2010a) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.
Wierda, W.G., Kipps, T.J., Mayer, J., Robak, T., Dyer, M.J., Furman, R.R., Hillmen, P., Stilgenbauer, S., Williams, C.D., Trneny, M., Cartron, G., Hernandez-Ilizaliturri, F.J., Padmanabhan, S., Chan, G.W., Gupta, I.V., Gorczyca, M.M., Davis, R.L., Losic, N., Lisby, S. & Österborg, A. (2010b) Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood, 116, 921.
Zenz, T., Busch, R., Fink, A., Winkler, D., Fischer, K., Bühler, A., Hoth, A., Fingerle-Rowson, G.R., Kneba, M., Boettcher, S., Jäger, U., Mendila, M., Wenger, M., Lichtern, P., Hallek, M., Döhner, H. & Stilgenbauer, S. (2010) Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLL8 trial of the GCLLSG. Blood, 116, 2427.